天域生物: 关于本次向特定对象发行A股股票摊薄即期回报及填补回报措施和相关主体承诺的公告

Core Viewpoint - Tianyu Biotechnology Co., Ltd. is issuing A-shares to specific investors, which will dilute immediate returns and affect key financial metrics, but the company has outlined measures to mitigate this impact [1][2][8]. Financial Impact Analysis - The issuance will increase the total share capital from 29,014.62 million shares to 36,117.45 million shares [5]. - The net profit attributable to shareholders, excluding non-recurring gains and losses, is projected to be -113.14 million yuan for 2024, with three scenarios for 2025: flat, 10% growth, and 20% growth [2][6]. - Under the flat scenario, basic and diluted earnings per share (EPS) will remain at -0.37 yuan, while under the 10% growth scenario, EPS will improve to -0.33 yuan [6]. - In the 20% growth scenario, EPS is projected to reach -0.30 yuan [6]. Necessity and Feasibility of the Issuance - The funds raised will be used to enhance liquidity and repay debts, improving the company's financial structure and risk resilience [8]. - The issuance aligns with the company's long-term development goals and shareholder interests [8]. Measures to Mitigate Dilution of Immediate Returns - The company plans to enhance governance structures to protect shareholder rights and ensure effective decision-making [9]. - It will implement strict management of raised funds to ensure efficient use and compliance with regulations [9]. - A profit distribution system will be established to ensure reasonable returns to shareholders, with a three-year shareholder return plan from 2025 to 2027 [11]. Commitments from Company Leadership - The actual controller and senior management have made commitments to ensure the effectiveness of measures to mitigate the dilution of immediate returns [12][12].